Based on the STAAR Surgical Company stock forecast from 7 analysts, the average analyst target price for STAAR Surgical Company is USD 24.20 over the next 12 months. STAAR Surgical Company’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of STAAR Surgical Company is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, STAAR Surgical Company’s stock price was USD 17.40. STAAR Surgical Company’s stock price has changed by +7.81% over the past week, -1.81% over the past month and -63.89% over the last year.
No recent analyst target price found for STAAR Surgical Company
No recent average analyst rating found for STAAR Surgical Company
Company Overview STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. Read Less
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-base...Read More
Frequently Asked Questions About STAAR Surgical Company (STAA) Stock
Based on ratings from 7 analysts STAAR Surgical Company's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, 2 sell and 6 hold ratings.
Unfortunately we do not have enough data on STAA's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for STAA is USD 24.20 over the next 12 months. The maximum analyst target price is USD 49 while the minimum anlayst target price is USD 16.
STAA stock's Price/Earning ratio is 50.66.
Our analysis grades STAA stock's Price / Earning ratio at F. This means that STAA stock's Price/Earning ratio is above 70% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this STAA may be a overvalued for its sector.
The last closing price of STAA's stock was USD 17.40.
The most recent market capitalization for STAA is USD 0.88B.
Based on targets from 7 analysts, the average taret price for STAA is projected at USD 24.20 over the next 12 months.
This means that STAA's stock price may go up by +39.08% over the next 12 months.
We can't find any ETFs which contains STAAR Surgical Company's stock.
As per our most recent records STAAR Surgical Company has 1,157 Employees.
STAAR Surgical Company's registered address is 25510 Commercentre Drive, Lake Forest, CA, United States, 92630.
You can get more information about it from STAAR Surgical Company's website at https://www.staar.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About STAAR Surgical Company (STAA) Stock
Based on ratings from 7 analysts STAAR Surgical Company's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, 2 sell and 6 hold ratings.
Unfortunately we do not have enough data on STAA's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for STAA is USD 24.20 over the next 12 months. The maximum analyst target price is USD 49 while the minimum anlayst target price is USD 16.
STAA stock's Price/Earning ratio is 50.66.
Our analysis grades STAA stock's Price / Earning ratio at F. This means that STAA stock's Price/Earning ratio is above 70% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this STAA may be a overvalued for its sector.
The last closing price of STAA's stock was USD 17.40.
The most recent market capitalization for STAA is USD 0.88B.
Based on targets from 7 analysts, the average taret price for STAA is projected at USD 24.20 over the next 12 months.
This means that STAA's stock price may go up by +39.08% over the next 12 months.
We can't find any ETFs which contains STAAR Surgical Company's stock.
As per our most recent records STAAR Surgical Company has 1,157 Employees.
STAAR Surgical Company's registered address is 25510 Commercentre Drive, Lake Forest, CA, United States, 92630.
You can get more information about it from STAAR Surgical Company's website at https://www.staar.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for STAA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
